​

Phathom Pharmaceuticals (PHAT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PHAT Stock Forecast

Phathom Pharmaceuticals (PHAT) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $22.00, with a high of $28.00 and a low of $18.00. This represents a 143.63% increase from the last price of $9.03.

$5 $10 $15 $20 $25 $30 High: $28 Avg: $22 Low: $18 Last Closed Price: $9.03

PHAT Stock Rating

Phathom Pharmaceuticals stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (88.89%), 1 Hold (11.11%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 1 8 Strong Sell Sell Hold Buy Strong Buy

PHAT Price Target Upside V Benchmarks

TypeNameUpside
StockPhathom Pharmaceuticals143.63%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts3310
Avg Price Target$21.33$21.33$22.20
Last Closing Price$9.03$9.03$9.03
Upside/Downside136.21%136.21%145.85%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 26271--10
Jun, 26271--10
May, 26271--10
Apr, 26281--11
Mar, 26182--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 31, 2026Chase KnickerbockerCraig-Hallum$20.00$9.32114.59%121.48%
Jul 31, 2026Guggenheim$22.00$9.03143.63%143.63%
Jul 30, 2026Needham$22.00$9.03143.63%143.63%
Mar 27, 2026Jenna DavidnerBarclays$18.00$10.5870.13%99.34%
Feb 26, 2026Annabel SamimyStifel Nicolaus$28.00$13.62105.58%210.08%
Dec 11, 2025Martin AusterRaymond James$28.00$14.5692.31%210.08%
Dec 08, 2025Jenna DavidnerBarclays$16.00$14.907.38%77.19%
Oct 31, 2025Chase KnickerbockerCraig-Hallum$22.00$13.7659.88%143.63%
Oct 31, 2025H.C. Wainwright$26.00$13.3195.34%187.93%
Oct 30, 2025Yatin SunejaGuggenheim$20.00$13.3150.26%121.48%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 31, 2026Craig-HallumBuyBuyhold
Jul 31, 2026H.C. WainwrightBuyBuyhold
Jun 17, 2026H.C. WainwrightBuyBuyhold
Mar 27, 2026BarclaysNeutralOverweightupgrade
Jan 14, 2026Cantor FitzgeraldOverweightOverweighthold
Dec 11, 2025Raymond JamesStrong Buyinitialise
Dec 08, 2025BarclaysNeutralinitialise
Oct 31, 2025Craig-HallumBuyBuyhold
Oct 31, 2025H.C. WainwrightBuyBuyhold
Oct 30, 2025GuggenheimBuyBuyhold

Financial Forecast

EPS Forecast

$-8 $-6 $-4 $-2 $0 $2 $3 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.93$-5.29$-3.03---
Avg Forecast$-3.72$-5.41$-4.12$-1.61$0.70$1.82
High Forecast$-3.32$-3.78$-2.88$-0.27$1.68$2.48
Low Forecast$-4.12$-7.38$-5.61$-2.31$-0.28$1.27
Surprise %5.65%-2.22%-26.46%---

Revenue Forecast

$0 $200M $400M $600M $800M $1B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$682.00K$55.25M$175.11M---
Avg Forecast$394.86K$51.63M$175.07M$383.68M$599.45M$763.24M
High Forecast$437.16K$55.00M$218.32M$391.75M$614.74M$976.80M
Low Forecast$347.85K$46.69M$131.11M$375.62M$584.16M$586.59M
Surprise %72.72%7.02%0.02%---

Net Income Forecast

$-400M $-290M $-180M $-70M $40M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-201.59M$-334.33M----
Avg Forecast$-201.59M$-339.44M$-217.81M$-66.16M$35.90M$93.35M
High Forecast$-170.43M$-193.93M$-147.63M$-13.73M$86.01M$127.30M
Low Forecast$-211.45M$-378.30M$-287.99M$-118.59M$-14.21M$65.26M
Surprise %--1.51%----

PHAT Forecast FAQ

Is Phathom Pharmaceuticals stock a buy?

Phathom Pharmaceuticals stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Phathom Pharmaceuticals is a favorable investment for most analysts.

What is Phathom Pharmaceuticals's price target?

Phathom Pharmaceuticals's price target, set by 9 Wall Street analysts, averages $22 over the next 12 months. The price target range spans from $18 at the low end to $28 at the high end, suggesting a potential 143.63% change from the previous closing price of $9.03.

How does Phathom Pharmaceuticals stock forecast compare to its benchmarks?

Phathom Pharmaceuticals's stock forecast shows a 143.63% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Phathom Pharmaceuticals over the past three months?

  • July 2026: 20.00% Strong Buy, 70.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 20.00% Strong Buy, 70.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 20.00% Strong Buy, 70.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.

What is Phathom Pharmaceuticals’s EPS forecast?

Phathom Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.61, marking a -46.86% decrease from the reported $-3.03 in 2025. Estimates for the following years are $0.7 in 2027, and $1.82 in 2028.

What is Phathom Pharmaceuticals’s revenue forecast?

Phathom Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $383.68M, reflecting a 119.11% increase from the reported $175.11M in 2025. The forecast for 2027 is $599.45M, and $763.24M for 2028.

What is Phathom Pharmaceuticals’s net income forecast?

Phathom Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-66.161M, representing a 0% decrease from the reported $0 in 2025. Projections indicate $35.9M in 2027, and $93.35M in 2028.